W. Young

发表

Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa.

B. Katz, R. Mackman, C. Luong, 2001, Journal of medicinal chemistry.

Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability.

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2016, Bioorganic & medicinal chemistry letters.

Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor

John C. Davis, P. Kuebler, J. Lubach, 2011, Drug Metabolism and Disposition.

Quinolones as HCV NS5B polymerase inhibitors.

J. R. Somoza, J. Janc, K. Brameld, 2011, Bioorganic & medicinal chemistry letters.

BTK small molecule inhibitors induce a distinct pancreatic toxicity in rats

Adam R. Johnson, Li-chuan, M. Hedehus, 2016 .

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.

Adam R. Johnson, Z. Modrušan, J. DeVoss, 2017, JCI insight.

Tetracyclic spirooxindole blockers of hNaV1.7: activity in vitro and in CFA-induced inflammatory pain model

Tom H. H. Hsieh, Shaoyi Sun, Jianmin Fu, 2013, Medicinal Chemistry Research.

Human T Cells Armed with Her2/neu Bispecific Antibodies Divide, Are Cytotoxic, and Secrete Cytokines with Repeated Stimulation

L. Lum, P. Davol, W. Young, 2006, Clinical Cancer Research.

Human TCells Armedwith Her 2 / neu Bispecific Antibodies Divide , Are Cytotoxic , and Secrete Cytokineswith Repeated Stimulation

L. Lum, P. Davol, W. Young, 2006 .

Dibasic inhibitors of human mast cell tryptase. Part 2: structure-activity relationships and requirements for potent activity.

P. J. Simpson, A. Gangloff, L. Cregar, 2000, Bioorganic & medicinal chemistry letters.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Adam R. Johnson, Lisa L. Smith, J. Byrd, 2018, Blood.

Discovery of XEN907, a spirooxindole blocker of NaV1.7 for the treatment of pain.

Jianmin Fu, W. Young, Shifeng Liu, 2011, Bioorganic & medicinal chemistry letters.

Bruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats

Adam R. Johnson, M. Hedehus, R. Carano, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor

P. Kuebler, J. Lubach, H. Wong, 2011 .

Discovery of novel hydroxy pyrazole based factor IXa inhibitor.

J. Janc, B. Katz, P. Sprengeler, 2006, Bioorganic & medicinal chemistry letters.

Efforts toward oral bioavailability in factor VIIa inhibitors.

Liang Liu, C. O'bryan, E. Leahy, 2006, Bioorganic & medicinal chemistry letters.

Factor VIIa inhibitors: improved pharmacokinetic parameters.

J. Janc, Liang Liu, B. Katz, 2006, Bioorganic & medicinal chemistry letters.

Factor VIIa inhibitors: gaining selectivity within the trypsin family.

J. Janc, B. Katz, Jie Tang, 2006, Bioorganic & medicinal chemistry letters.

An expeditious synthesis of 2-amino-4(3)-oxo-5-pyrrolo[3,2-]pyrimidine (9-Deazaguanine)

W. Young, E. Taylor, C. C. Ward, 1993 .

Potent 4-amino-5-azaindole factor VIIa inhibitors.

E. Gjerstad, E. Leahy, P. Sprengeler, 2006, Bioorganic & medicinal chemistry letters.

Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.

Liang Liu, J. Mordenti, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

Discovery of novel heterocyclic factor VIIa inhibitors.

B. Katz, P. Sprengeler, J. Hendrix, 2006, Bioorganic & medicinal chemistry letters.

Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model.

J. Janc, Liang Liu, S. Hanson, 2006, Bioorganic & medicinal chemistry letters.

Optimization of a screening lead for factor VIIa/TF.

E. Leahy, P. Sprengeler, W. Shrader, 2001, Bioorganic & medicinal chemistry letters.

Novel 5-azaindole factor VIIa inhibitors.

B. Katz, E. Leahy, P. Sprengeler, 2006, Bioorganic & Medicinal Chemistry Letters.

Neutral inhibitors of the serine protease factor Xa.

P. Sprengeler, W. Shrader, K. Elrod, 2001, Bioorganic & medicinal chemistry letters.

Perspectives on factor Xa inhibition.

P. Sprengeler, P A Sprengeler, R Rai, 2001, Current medicinal chemistry.

Expression, Crystallization, and Three-dimensional Structure of the Catalytic Domain of Human Plasma Kallikrein*

Steven R. Williams, D. Jeffery, M. Mcgrath, 2005, Journal of Biological Chemistry.

Small molecule inhibitors of plasma kallikrein.

B. Katz, J. Mordenti, J. Sukbuntherng, 2006, Bioorganic & medicinal chemistry letters.

Development of potent and selective factor Xa inhibitors.

W D Shrader, B. Katz, C. Luong, 2001, Bioorganic & medicinal chemistry letters.

Pyrrolo[3,2-d]pyrimidine Folate Analogs: "Inverted" Analogs of the Cytotoxic Agent LY231514

W. Young, E. Taylor, 1995 .

Discovery of novel heterocyclic factor VIIa inhibitors.

B. Katz, P. Sprengeler, J. Hendrix, 2006, Bioorganic & medicinal chemistry letters.

Novel 5-azaindole factor VIIa inhibitors.

B. Katz, E. Leahy, P. Sprengeler, 2006, Bioorganic & medicinal chemistry letters.

A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.

J. Janc, S. Sideris, B. Katz, 2002, Journal of molecular biology.

Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

Tyler Risom, Zhaoyang Wen, Ignacio Aliagas, 2011, ACS medicinal chemistry letters.

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

Adam R. Johnson, BinQing Wei, C. Eigenbrot, 2018, Journal of medicinal chemistry.

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Brandon J. Bravo, L. Diehl, S. Hymowitz, 2011, Nature chemical biology.

Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2017, ACS medicinal chemistry letters.

Stereocontrolled Syntheses of C-Aryl Taxanes By Intramolecular Heck Olefination. Novel Instances of Diastereofacial Guidance By Proximal Coordination

J. Masters, S. Danishefsky, W. Young, 1995 .

Dibasic inhibitors of human mast cell tryptase. Part 3: identification of a series of potent and selective inhibitors containing the benzamidine functionality.

A. Gangloff, L. Cregar, K. Rice, 2001, Bioorganic & medicinal chemistry letters.

Novel entry to the tropane system by reaction of rhodium(II) acetate stabilized vinylcarbenoids with pyrroles

H. Davies, W. Young, H. D. Smith, 1989 .

Synthesis of (.+-.)-ferruginine and (.+-.)-anhydroecgonine methyl-ester by a tandem cyclopropanation/Cope rearrangement

H. Davies, W. Young, E. Saikali, 1991 .

Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2020, ACS medicinal chemistry letters.

Syntheses of a Regioisomer of N-{4-[2-(2-Amino-4(3H)-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic Acid (LY231514), an Active Thymidylate Synthase Inhibitor and Antitumor Agent

W. Young, E. Taylor, H. Patel, 1993 .

The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells

A. Zarrin, S. Warming, J. Hackney, 2020, Science Signaling.

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.

Adam R. Johnson, C. Eigenbrot, A. Estevez, 2016, ACS chemical biology.

3-heterocyclyl quinolone inhibitors of the HCV NS5B polymerase.

J. Janc, J. Ho, K. Brameld, 2012, Bioorganic & medicinal chemistry letters.

Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.

S. Hymowitz, J. Lubach, K. Reif, 2015, Bioorganic & medicinal chemistry letters.

Strategies to Mitigate the Bioactivation of Aryl Amines.

Matthew L Landry, Huifen Chen, Shuguang Ma, 2020, Chemical research in toxicology.

Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).

Erik Verner, James W Janc, J. R. Somoza, 2004, Journal of Molecular Biology.

Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.

J. Janc, B. Katz, E. Verner, 2006, Bioorganic & medicinal chemistry letters.

Medicinal Chemistry: Where Are All the Women?

M. Bolognesi, D. Huryn, W. Young, 2017, ACS medicinal chemistry letters.

Effect of anti-prostaglandin therapy in experimental parainfluenza type 3 pneumonia in weaned, conventional calves

I. Selman, W. Young, H. A. Gibbs, 1984, Veterinary Record.

Advances toward COVID-19 Therapies Special Issue Call for Papers.

N. Neamati, N. Meanwell, Shaomeng Wang, 2020, Journal of medicinal chemistry.